Findings

What do systematic reviews say?

537 questions · 560 findings · 45 reviews · Common Mental Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 105 · 18.8%GRADE not reported 8 · 1.4%Very low 170 · 30.4%Low 153 · 27.3%Moderate 94 · 16.8%High 30 · 5.4%

Comparison 10: RIMAs vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 695 participants
Low

Comparison 10: RIMAs vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 724 participants
Very low

Comparison 10: RIMAs vs placebo

Clinical Global Impressions ‐ Improvement of condition (CGI‐I) Rating of 1 = very much improved to 7 = very much worse · adults with SAnD

Comparison 10: RIMAs probably leads to higher clinical Global Impressions scale change item (CGI‐I): no. of… compared with placebo (moderate certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 1.5 [1.12, 2]
1 study · 90 participants
Moderate

Comparison 11: SARIs vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 102 participants
Very low

Comparison 12: SNRIs vs placebo

Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD

Comparison 12: SNRIs showed no clear difference in global Impressions scale change item (CGI‐I or similar): no. of… compared with placebo (low certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 1.3 [0.85, 1.99]
4 studies · 1173 participants
Low

Comparison 12: SNRIs vs placebo

Withdrawals due to adverse events · adults with SAnD

Comparison 12: SNRIs probably leads to higher dropouts due to adverse events (acute phase) compared with placebo (moderate certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 3.23 [2.15, 4.86]
4 studies · 1213 participants
Moderate

Comparison 12: SNRIs vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 902 participants
Moderate

Comparison 12: SNRIs vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 261 participants
Low

Comparison 12: SNRIs vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 261 participants
Low

Comparison 13: SSRIs vs placebo

Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD

It is very uncertain whether comparison 13: SSRIs changes global Impressions scale change item (CGI‐I or similar): no. of… compared with placebo (very low certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 1.65 [1.48, 1.85]
24 studies · 4984 participants
Very low

Comparison 2: anticonvulsants/GABAs vs placebo

Withdrawals due to adverse events · adults with SAnD

It is very uncertain whether comparison 2: anticonvulsants/GABAs changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 2.9 [0.92, 9.14]
3 studies · 532 participants
Very low

Comparison 13: SSRIs vs placebo

Relapse · adults with SAnD

Comparison 13: SSRIs probably leads to lower relapse rate ‐ no. relapsed compared with placebo (moderate certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 0.34 [0.22, 0.5]
3 studies · 389 participants
Moderate

Comparison 13: SSRIs vs placebo

Withdrawals due to adverse events · adults with SAnD

Comparison 13: SSRIs may leads to higher dropouts due to adverse events (acute phase) compared with placebo (low certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 2.59 [1.97, 3.39]
24 studies · 5131 participants
Low

Comparison 13: SSRIs vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
14 studies · 1990 participants
Low

Comparison 13: SSRIs vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 1173 participants
Low

Comparison 13: SSRIs vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 1173 participants
Low

Comparison 13: SSRIs vs placebo

Clinical Global Impressions scale change item (CGI‐I): no. of responders (long term) Post‐treatment: 1‐4 months · adults with SAnD

Comparison 13: SSRIs may leads to higher clinical Global Impressions scale change item (CGI‐I): no. of… compared with placebo (low certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 1.27 [1.07, 1.51]
4 studies · 806 participants
Low

Comparison 13: SSRIs vs placebo

Dropouts due to adverse events · adults with SAnD

It is very uncertain whether comparison 13: SSRIs changes dropouts due to adverse events (long term) Post‐treatment: 1‐4 months compared with placebo (very low certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 1.17 [0.43, 3.18]
3 studies · 1274 participants
Very low

Comparison 14: GW876008 vs placebo

Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD

Comparison 14: GW876008 showed no clear difference in global Impressions scale change item (CGI‐I or similar): no. of… compared with placebo (moderate certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 0.83 [0.58, 1.19]
1 study · 250 participants
Moderate

Comparison 14: GW876008 vs placebo

Withdrawals due to adverse events · adults with SAnD

Comparison 14: GW876008 showed no clear difference in dropouts due to adverse events (acute phase) compared with placebo (low certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 2.95 [0.67, 13.02]
1 study · 252 participants
Low